ImmunoCellular Investor Presentation

•

3 recomendaciones•448 vistas

IMUC is a clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers.

Empresariales Tecnología

January 2010 Manish Singh, PhD President and CEO OTC BB: IMUC.OB www.imuc.com

SEC Disclaimer Statement ,[object Object],January 2010

Cancer Stem Cells: Good Guys Turned Bad ,[object Object],[object Object],January 2010 Targeting CSCs may significantly delay or prevent disease recurrences. Normal Stem Cell mutations Cancer Stem Cell Mature Tissue Bulk Tumor Progenitor cells

Technology Overview: Utilizing Both Arms of Immune System ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

ICT-107: Dendritic Cell-Based Vaccine Targeting Cancer Stem Cells and Tumor Associated Antigens January 2010 Antigens Tumor Expression CSC Expression gp100 Melanoma, brain cancer Trp-2 Melanoma and brain cancer High Her-2/neu Breast, ovarian cancer Medium MAGE-1 Melanoma, brain cancer AIM Breast, ovarian, colon, brain High IL-13aR2 Brain cancer

January 2010 Significant Improvement in Progression-Free Survival (Compared to Historical Controls Using Standard of Care) Radiation + Temozolomide* Radiation + Temozolomide +ICT-107 ,[object Object],[object Object]

Summary of Clinical Data: Progression-Free and Overall Survival January 2010 SOC = Standard of care (surgery + radiation + Temozolomide) Newly Diagnosed (16) SOC + ICT-107 Historical Control (SOC) Median PFS (months) 19.0 6.9 Median OS (months) > 21 14.2 % Survival at 12 months 94% 60% % Survival at 21 months 80% 30% Recurrent (3) Median OS (months) 30.5 7.0 (9.2 with Avastin+SOC)

ICT-121: Cancer Stem Cell Vaccine ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010 Potential Blockbuster Product

Summary of Antibody Programs January 2010 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Value Creation Catalysts in Next 12 Months ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

Management Team ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

Key Opinion Leaders ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

Financial Position and Capitalization ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

Summary ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

Más contenido relacionado

La actualidad más candente

Global cancer immunotherapy market outlook 2020KuicK Research

Inovio Pharmaceuticals PresentationInovio Pharmaceuticals, Inc.

Quantum ImmunlogicsPro-Active Capital Resources Group

Global cancer immunotherapy market outlook 2020KuicK Research

Inovio - Corporate Presentation - July 2014Company Spotlight

Inovio Pharmaceuticals - Revolutionizing VaccinesCompany Spotlight

Taking Immunotherapy to the Next levelCompany Spotlight

Inmuno oncologyLuis Miguel Zetina Toache

Cancer immunomodulators market & pipeline insight 2020KuicK Research

Inovio Pharmaceuticals - October 2015Company Spotlight

Global dendritic cell cancer vaccine market outlook 2020KuicK Research

GenomeTrakr: Whole-Genome Sequencing for Food Safety and A New Way Forward in...ExternalEvents

Presentaiton inovio 314Company Spotlight

Inovio sep13presCompany Spotlight

SwaanUniversity of Maryland Baltimore

1810 3 q-2018-presentation-v7targovax2017

Download Global cancer immunotoxins market & clinical pipeline insight 2020KuicK Research

1711 3 q presentation v7 uten backuptargovax2017

Btp a poc nanotechnology company.pptxRaouf Guirguis

La actualidad más candente (19)

Global cancer immunotherapy market outlook 2020

Inovio Pharmaceuticals Presentation

Quantum Immunlogics

Global cancer immunotherapy market outlook 2020

Inovio - Corporate Presentation - July 2014

Inovio Pharmaceuticals - Revolutionizing Vaccines

Taking Immunotherapy to the Next level

Inmuno oncology

Cancer immunomodulators market & pipeline insight 2020

Inovio Pharmaceuticals - October 2015

Global dendritic cell cancer vaccine market outlook 2020

GenomeTrakr: Whole-Genome Sequencing for Food Safety and A New Way Forward in...

Presentaiton inovio 314

Inovio sep13pres

Swaan

1810 3 q-2018-presentation-v7

Download Global cancer immunotoxins market & clinical pipeline insight 2020

1711 3 q presentation v7 uten backup

Btp a poc nanotechnology company.pptx

Más de Chelli Miller

Can you stand out in the Sea of JP Morgan Healthcare Conference Suits?Chelli Miller

Swimming with the sharks in med schoolChelli Miller

Another Year of Top Residencies for SabaChelli Miller

Xchange reception @ JP Morgan Healthcare Conference Week!Chelli Miller

Exclusive mHealth Programming @ the AdaMed2014 ConferenceChelli Miller

AdvaMed2014 Invites mHealth to Chicago!Chelli Miller

DEVELOPMENT OF ESSENTIAL SAMPLE PREPARATION TECHNIQUES IN PROTEOMICS USING UL...Chelli Miller

Pharmatimes articleChelli Miller

Abviva, Inc. (PK ABVV) presentation OneMedForum-New YorkChelli Miller

Más de Chelli Miller (9)

Can you stand out in the Sea of JP Morgan Healthcare Conference Suits?

Swimming with the sharks in med school

Another Year of Top Residencies for Saba

Xchange reception @ JP Morgan Healthcare Conference Week!

Exclusive mHealth Programming @ the AdaMed2014 Conference

AdvaMed2014 Invites mHealth to Chicago!

DEVELOPMENT OF ESSENTIAL SAMPLE PREPARATION TECHNIQUES IN PROTEOMICS USING UL...

Pharmatimes article

Abviva, Inc. (PK ABVV) presentation OneMedForum-New York

Último

Guide Complete Set of Residential Architectural Drawings PDFChandresh Chudasama

Darshan Hiranandani [News About Next CEO].pdfShashank Mehta

Fordham -How effective decision-making is within the IT department - Analysis...Peter Ward

Buy gmail accounts.pdf Buy Old Gmail AccountsBuy Verified Accounts

Annual General Meeting Presentation SlidesKeppelCorporation

Corporate Profile 47Billion Information TechnologyData Analytics Company - 47Billion Inc.

FULL ENJOY Call girls in Paharganj Delhi | 8377087607dollysharma2066

8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCRashishs7044

Cybersecurity Awareness Training Presentation v2024.03DallasHaselhorst

Appkodes Tinder Clone Script with Customisable Solutions.pptxappkodes

MAHA Global and IPR: Do Actions Speak Louder Than Words?Olivia Kresic

Call Girls Contact Number Andheri 9920874524najka9823

Unlocking the Future: Explore Web 3.0 Workshop to Start Earning Today!Doge Mining Website

PB Project 1: Exploring Your Personal BrandSharisaBethune

Entrepreneurship lessons in PhilippinesDavidSamuel525586

Church Building Grants To Assist With New Construction, Additions, And Restor...Americas Got Grants

Chapter 9 PPT 4th edition.pdf internal auditNhtLNguyn9

Enjoy ➥8448380779▻ Call Girls In Sector 18 Noida Escorts Delhi NCRStunning ➥8448380779▻ Call Girls In Hauz Khas Delhi NCR

PSCC - Capability Statement PresentationAnamaria Contreras

(Best) ENJOY Call Girls in Faridabad Ex | 8377087607dollysharma2066

ImmunoCellular Investor Presentation

1. January 2010 Manish Singh, PhD President and CEO OTC BB: IMUC.OB www.imuc.com

6. ICT-107: Dendritic Cell-Based Vaccine Targeting Cancer Stem Cells and Tumor Associated Antigens January 2010 Antigens Tumor Expression CSC Expression gp100 Melanoma, brain cancer Trp-2 Melanoma and brain cancer High Her-2/neu Breast, ovarian cancer Medium MAGE-1 Melanoma, brain cancer AIM Breast, ovarian, colon, brain High IL-13aR2 Brain cancer

8. Summary of Clinical Data: Progression-Free and Overall Survival January 2010 SOC = Standard of care (surgery + radiation + Temozolomide) Newly Diagnosed (16) SOC + ICT-107 Historical Control (SOC) Median PFS (months) 19.0 6.9 Median OS (months) > 21 14.2 % Survival at 12 months 94% 60% % Survival at 21 months 80% 30% Recurrent (3) Median OS (months) 30.5 7.0 (9.2 with Avastin+SOC)

10.

11.

12.

13.

14.

15.

ImmunoCellular Investor Presentation

Recomendados

Recomendados

Más contenido relacionado

La actualidad más candente

La actualidad más candente (19)

Similar a ImmunoCellular Investor Presentation

Similar a ImmunoCellular Investor Presentation (20)

Más de Chelli Miller

Más de Chelli Miller (9)

Último

Último (20)

ImmunoCellular Investor Presentation